Page 96 - The Flying Publisher Guide to Hepatitis C Treatment

96 | Hepatitis C Treatment

Matsumoto A, Ichikawa T, Nakao K, et al. Interferon--induced mTOR activation
is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-
independent pathway. J Gastroenterol 2009;44:856-63.
Matsuura K, Tanaka Y, Hasegawa I, et al. Abbott RealTime Hepatitis C virus (HCV)
and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of
sustained virological response to pegylated interferon and ribavirin in
chronic hepatitis C patients. J Clin Microbiol 2009;47:385-9.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and
ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-
38.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a
with ribavirin for treatment of hepatitis C infection. N Engl J Med
2009;361:580–93.
McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy
enhances sustained response in genotype-1-infected patients with chronic
hepatitis C. Gastroenterology 2002;123:1061-9.
McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated
chronic HCV infection. N Engl J Med 2010;362:1292-303.
McHutchison JG, Poynard T, Pianko S, et al. Impact of interferon plus Ribavirin
on response to therapy in black patients with hepatitis C. Gastroenterology
2000;119:1317-23.
Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained
virological response to therapy with pegylated interferon plus ribavirin in
patients coinfected with hepatitis C virus and HIV. Clin Infect Dis
2010;51:1209-16.
Meyer DF, Tobias H, Min AD, et al. Retreatment of patients nonresponsive to
pegylated interferon and ribavirin with daily high-dose consensus
interferon. Hepat ResTreat 2010;537:827.
Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis
C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699–
714.
Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency
virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus
infected patients. Gut 2003;52:1035-40.
Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon
alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin
Gastroenterol Hepatol 2009;7:212-8.
Ogawa E, Furusyo N, Toyoda K, et al. Excellent superiority and specificity of
COBAS TaqMan HCV assay in an early viral kinetic change during pegylated
interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol
2010;10:38-46.
Ohta T, Sakaguchi K, Fujiwara A, et al. Simple surrogate index of the fibrosis
stage in chronic hepatitis C patients using platelet count and serum
albumin level. Acta Med Okayama 2006;60:77-84.
Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu JX, Bandi P, Robek MD. Mechanisms
of signal transduction: interleukin-29 functions cooperatively with
Interferon to induce antiviral gene expression and inhibit hepatitis C virus
replication. J Biol Chem 2008;283:30079-89.